{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:41:24Z","timestamp":1780119684102,"version":"3.54.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.4065\/75.8.821","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:17:28Z","timestamp":1232759848000},"page":"821-829","source":"Crossref","is-referenced-by-count":38,"title":["Prevention and Treatment of Osteoporosis in Women With Breast Cancer"],"prefix":"10.4065","volume":"75","author":[{"given":"Betty A.","family":"Mincey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Moraghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.4065\/75.8.821_bib1","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00007632-199712151-00002","article-title":"Epidemiology of spinal osteoporosis","volume":"22","author":"Melton","year":"1997","journal-title":"Spine"},{"key":"10.4065\/75.8.821_bib2","first-page":"1","article-title":"Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis: report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.4065\/75.8.821_bib3","first-page":"157","volume":"2","author":"AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis","year":"1996","journal-title":"Endocr Pract"},{"key":"10.4065\/75.8.821_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3181\/00379727-217-44203","article-title":"Alternatives to estrogen for menopausal women","volume":"217","author":"Kessel","year":"1998","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.4065\/75.8.821_bib5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<830::AID-CNCR2>3.0.CO;2-M","article-title":"Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked","volume":"83","author":"Lappe","year":"1998","journal-title":"Cancer"},{"key":"10.4065\/75.8.821_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer statistics, 2000","volume":"50","author":"Greenlce","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"10.4065\/75.8.821_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1262::AID-CNCR28>3.0.CO;2-2","article-title":"The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States","volume":"83","author":"Bland","year":"1998","journal-title":"Cancer"},{"key":"10.4065\/75.8.821_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-93-1-109","article-title":"Gonadal dysfunction in patients receiving chemotherapy for cancer","volume":"93","author":"Schilsky","year":"1980","journal-title":"Ann Iniern Med"},{"key":"10.4065\/75.8.821_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-3-642-84745-5_33","article-title":"Long-term sequelae from adjuvant chemotherapy","volume":"127","author":"Valagussa","year":"1993","journal-title":"Recent Results Cancer Res"},{"key":"10.4065\/75.8.821_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07357909809039747","article-title":"Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy","volume":"16","author":"Headley","year":"1998","journal-title":"Cancer Invest"},{"key":"10.4065\/75.8.821_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"10.4065\/75.8.821_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0959-8049(97)10135-6","article-title":"Bone loss induced by cancer treatment and its management","volume":"34","author":"Delmas","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.4065\/75.8.821_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.4065\/75.8.821_bib14","series-title":"Physician's Guide to Prevention and Treatment of Osteoporosis","author":"National Osteoporosis Foundation","year":"1998"},{"key":"10.4065\/75.8.821_bib15","first-page":"1491","article-title":"Estrogen replacement therapy for breast cancer patients","volume":"11","author":"Coldiu","year":"1997","journal-title":"Oncology (Hunting)"},{"key":"10.4065\/75.8.821_bib16","first-page":"1498","article-title":"In review of: Colditz.15","volume":"11","author":"Love","year":"1997","journal-title":"Oncology (Huntingl)"},{"key":"10.4065\/75.8.821_bib17","first-page":"1501","article-title":"In review of: Cotditz.15","volume":"11","author":"Cobleigh","year":"1997","journal-title":"Oncology (Huntingl)"},{"key":"10.4065\/75.8.821_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1043-2760(98)00003-4","article-title":"Hormone replacement therapy in women with previous breast cancer","volume":"9","author":"Marsden","year":"1998","journal-title":"Trends Endocrinol Metab"},{"key":"10.4065\/75.8.821_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Early Postmenopausal Intervention Cohort Study Group. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib20","first-page":"253","article-title":"Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Alendronatc prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial, Ann Intern Med"},{"key":"10.4065\/75.8.821_bib21","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronatc treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chcsnut","year":"1995","journal-title":"Am J Med"},{"key":"10.4065\/75.8.821_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis [published correction appears in Bone. 1996;19:78|","volume":"18","author":"Devogclacr","year":"1996","journal-title":"Bone"},{"key":"10.4065\/75.8.821_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"10.4065\/75.8.821_bib25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Alendroriate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engt J Med"},{"key":"10.4065\/75.8.821_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.4065\/75.8.821_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/17453674.1997.11744760","article-title":"A double blind study of intranasal calcitonin for established postmenopausal osteoporosis","volume":"275","author":"Kapctanos","year":"1997","journal-title":"Act Orthop Scand Suppl"},{"key":"10.4065\/75.8.821_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/8756-3282(95)00447-5","article-title":"Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis","volume":"18","author":"Thamsborg","year":"1996","journal-title":"Bone"},{"key":"10.4065\/75.8.821_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcalonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"key":"10.4065\/75.8.821_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.4065\/75.8.821_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial","volume":"276","author":"Writing Group for the PEPI Trial","year":"1996","journal-title":"JAMA"},{"key":"10.4065\/75.8.821_bib32","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D and calcium to prevent hip fractures in elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1359\/jbmr.1998.13.2.168","article-title":"Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women","volume":"13","author":"Riggs","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.4065\/75.8.821_bib34","first-page":"1","article-title":"NIH Consens Statement [online]","volume":"12","author":"Optimal calcium intake","year":"1994","journal-title":"June 6-8"},{"key":"10.4065\/75.8.821_bib35","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/75.8.821_bib36","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.4065\/75.8.821_bib37","first-page":"1159","article-title":"Alendronate Osteoporosis Treatment Study Groups","volume":"277","author":"Karpf","year":"1997","journal-title":"Prevention of nonvertebral fractures by alendronate: a meta-analysis-JAMA"},{"key":"10.4065\/75.8.821_bib38","first-page":"1161","article-title":"United Kingdom experience with alendronate and oesophageal reactions","volume":"48","author":"Mackay","year":"1998","journal-title":"Br J Gen Pract"},{"key":"10.4065\/75.8.821_bib39","series-title":"Physicians' Desk Reference","first-page":"1660","year":"1998"},{"key":"10.4065\/75.8.821_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/75.8.821_bib41","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexaie, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premeno-pausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/75.8.821_bib42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Nad Cancer Inst"},{"key":"10.4065\/75.8.821_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(99)80344-1","article-title":"A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss","volume":"98","author":"Reginster","year":"1995","journal-title":"Am J Med"},{"key":"10.4065\/75.8.821_bib44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","article-title":"Effect of salcatonin given intranasally on early postmenopausal bone loss","volume":"299","author":"Overgaard","year":"1989","journal-title":"BMJ"},{"issue":"suppl 3","key":"10.4065\/75.8.821_bib45","first-page":"13","article-title":"Salmon-calcilonin nasal spray prevents vertebral fractures in established osteoporosis: further interim results of the PROOF study [abstract]","volume":"8","author":"Chesnut","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.4065\/75.8.821_bib46","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199804303381814","article-title":"Effects of raloxifene in postmenopausal women [letter]","volume":"338","author":"Delmas","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.4065\/75.8.821_bib48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF01806160","article-title":"Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen","volume":"39","author":"Kristcnsen","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.4065\/75.8.821_bib50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"suppl l","key":"10.4065\/75.8.821_bib51","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/0169-6009(92)90867-D","article-title":"Effect of ipriflavone on bone mass in elderly osteoporotic women","volume":"l9","author":"Passeri","year":"1992","journal-title":"Bone Miner"},{"key":"10.4065\/75.8.821_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5122(97)00059-5","article-title":"Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women","volume":"28","author":"Gambacciani","year":"1997","journal-title":"Maturitas"},{"key":"10.4065\/75.8.821_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00042192-199805010-00003","article-title":"Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause","volume":"5","author":"Gennari","year":"1998","journal-title":"Menopause"},{"key":"10.4065\/75.8.821_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-123-6-199509150-00001","article-title":"Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial","volume":"123","author":"Pak","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.4065\/75.8.821_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-129-1-199807010-00001","article-title":"The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis a randomized, controlled trial","volume":"129","author":"Reginster","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.4065\/75.8.821_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s001980050041","article-title":"Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy","volume":"8","author":"Meunier","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.4065\/75.8.821_bib58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4065\/75.8.821_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2796.1997.00133.x","article-title":"The prevention or treatment of age related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhIGF-I or rhTGF\u03b2): a perspective","volume":"242","author":"Boonen","year":"1997","journal-title":"J Iniern Med"},{"key":"10.4065\/75.8.821_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2265.1997.d01-1750.x","article-title":"Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study","volume":"46","author":"Gonnelli","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/75.8.821_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-129-2-199807150-00002","article-title":"Study of Osteoporotic Fractures Research Group. Physical activity and osteoporotic fracture risk in older women","volume":"129","author":"Gregg","year":"1998","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.4065\/75.8.821_bib62","first-page":"S157","article-title":"Effects of raloxifene (RLX), alendronate (ALN) and RLX+ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis [abstract]","volume":"14","author":"Johnell","year":"1999","journal-title":"J Bone Miner Res"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611630607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611630607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T08:50:53Z","timestamp":1545468653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611630607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["S0025619611630607"],"URL":"https:\/\/doi.org\/10.4065\/75.8.821","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}